These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9412398)

  • 1. [Coamoxiclav in the empirical monotherapy in outpatients with community acquired pneumonia].
    Yakovlev SV; Leshchenko IV; Kolesnikov VV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):19-22. PubMed ID: 9412398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and tolerance of coamoxiclav in community-acquired lower respiratory tract infections in children].
    Blokhin BM; Aldonina VV; Kozhukhova TM; Nikulin LA; Rumyantsev AG
    Antibiot Khimioter; 1997; 42(10):29-32. PubMed ID: 9412400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].
    Nonikov VE; Konstantinova TD; Lenkova NI; Minaev VI; Ritchik LA
    Antibiot Khimioter; 1997; 42(10):15-8. PubMed ID: 9412397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 6. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Program of empirical antibacterial therapy of community-acquired pneumonia].
    Suvorova MP; Iakovlev SV; Shakhova TV; Dvoretskiĭ LI
    Antibiot Khimioter; 1998; 43(7):31-5. PubMed ID: 9727165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
    Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
    J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical efficacy of ticarcillin/clavulanate in severe pneumonia].
    Iakovlev SV; Dvoretskiĭ LI; Shakhova TV
    Antibiot Khimioter; 2000; 45(3):30-4. PubMed ID: 10768064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].
    Sánchez ME; Gómez J; Gómez Vargas J; Baños V; Ruiz Gómez J; Muñoz L; Simarro E; Soto MC; Canteras M; Valdés M
    Rev Esp Quimioter; 1998 Jun; 11(2):132-8. PubMed ID: 9795298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
    Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.
    García Vázquez E; Mensa J; Martínez JA; Marcos MA; Puig J; Ortega M; Torres A
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):190-5. PubMed ID: 15782278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of community-acquired pneumopathies of adults in the city and at the hospital].
    Léophonte P
    Presse Med; 1998 Sep; 27 Suppl 4():5-7. PubMed ID: 9798473
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.